JP7169190B2 - Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 - Google Patents

Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 Download PDF

Info

Publication number
JP7169190B2
JP7169190B2 JP2018521308A JP2018521308A JP7169190B2 JP 7169190 B2 JP7169190 B2 JP 7169190B2 JP 2018521308 A JP2018521308 A JP 2018521308A JP 2018521308 A JP2018521308 A JP 2018521308A JP 7169190 B2 JP7169190 B2 JP 7169190B2
Authority
JP
Japan
Prior art keywords
seq
sequence
cdr
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018521308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537966A5 (enExample
JP2018537966A (ja
Inventor
ヂ－ヨン・ヤン
ゲイリー・ジェイ・ナベル
リン・シュ
ロニー・ウェイ
ファーウェイ・チウ
ヨッヘン・ベーニンガ
ヨッヘン・クルイプ
エアコーレ・ラオ
ディルク・ヴルフ・ロイシュナー
クリスティアン・バイル
クリスティアン・ランゲ
マーク・コナーズ
ジョン・アール・マスコラ
リチャード・エー・クープ
ジン・ホアン
ニコル・エー・ドリア－ローズ
トンキン・チョウ
ピーター・ディー・クォン
トゥ・ヤン・クォン
アマレンドラ・ペグー
マンガイアーカラシィ・アソカン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2018537966A publication Critical patent/JP2018537966A/ja
Publication of JP2018537966A5 publication Critical patent/JP2018537966A5/ja
Priority to JP2021016190A priority Critical patent/JP7328267B2/ja
Application granted granted Critical
Publication of JP7169190B2 publication Critical patent/JP7169190B2/ja
Priority to JP2023061823A priority patent/JP7724814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2018521308A 2015-10-25 2016-10-24 Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 Active JP7169190B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021016190A JP7328267B2 (ja) 2015-10-25 2021-02-04 Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質
JP2023061823A JP7724814B2 (ja) 2015-10-25 2023-04-06 Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
US62/246,113 2015-10-25
EP16305211.1 2016-02-24
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US62/322,029 2016-04-13
US201662331169P 2016-05-03 2016-05-03
US62/331,169 2016-05-03
PCT/US2016/058540 WO2017074878A1 (en) 2015-10-25 2016-10-24 Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021016190A Division JP7328267B2 (ja) 2015-10-25 2021-02-04 Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質

Publications (3)

Publication Number Publication Date
JP2018537966A JP2018537966A (ja) 2018-12-27
JP2018537966A5 JP2018537966A5 (enExample) 2019-11-21
JP7169190B2 true JP7169190B2 (ja) 2022-11-10

Family

ID=55588187

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018521308A Active JP7169190B2 (ja) 2015-10-25 2016-10-24 Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質
JP2021016190A Active JP7328267B2 (ja) 2015-10-25 2021-02-04 Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質
JP2023061823A Active JP7724814B2 (ja) 2015-10-25 2023-04-06 Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021016190A Active JP7328267B2 (ja) 2015-10-25 2021-02-04 Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質
JP2023061823A Active JP7724814B2 (ja) 2015-10-25 2023-04-06 Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質

Country Status (31)

Country Link
US (4) US20190054182A1 (enExample)
EP (2) EP3365366B1 (enExample)
JP (3) JP7169190B2 (enExample)
KR (1) KR102687212B1 (enExample)
CN (4) CN116789841A (enExample)
AR (1) AR106466A1 (enExample)
AU (2) AU2016347058B2 (enExample)
BR (1) BR112018008011A2 (enExample)
CA (1) CA3002664A1 (enExample)
CL (1) CL2018001065A1 (enExample)
CO (1) CO2018005337A2 (enExample)
CR (1) CR20180288A (enExample)
DO (1) DOP2018000102A (enExample)
EA (1) EA201891028A1 (enExample)
ES (1) ES2894304T3 (enExample)
HR (1) HRP20211528T1 (enExample)
HU (1) HUE056608T2 (enExample)
IL (2) IL301140A (enExample)
MA (1) MA42641A1 (enExample)
MX (2) MX2018005048A (enExample)
MY (1) MY192278A (enExample)
NZ (1) NZ781602A (enExample)
PE (1) PE20181167A1 (enExample)
PH (1) PH12018500873A1 (enExample)
PL (1) PL3365366T3 (enExample)
RS (1) RS62437B1 (enExample)
SG (1) SG11201803324VA (enExample)
SI (1) SI3365366T1 (enExample)
TW (3) TW202442675A (enExample)
UY (1) UY36965A (enExample)
WO (1) WO2017074878A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021072847A (ja) * 2015-10-25 2021-05-13 サノフイＳａｎｏｆｉ Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
WO2019135921A1 (en) * 2017-12-21 2019-07-11 Aaron Diamond Aids Research Center Bispecific hiv-1-neutralizing antibodies
EP3778630A1 (en) * 2014-02-28 2021-02-17 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
CN115010805B (zh) 2015-11-03 2025-01-28 美国政府(由卫生和人类服务部的部长所代表) Hiv-1 gp41中和抗体及其用途
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
HUE063824T2 (hu) * 2016-04-13 2024-02-28 Sanofi Sa Trispecifikus és/vagy trivalens kötõfehérjék
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US11845787B2 (en) * 2017-03-27 2023-12-19 The Wistar Institute Of Anatomy And Biology DNA antibody constructs for use against HIV
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
JP7036909B2 (ja) * 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
JP2021507717A (ja) * 2017-12-18 2021-02-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ 抗原結合性ポリペプチド
EP3737949A1 (en) 2018-01-12 2020-11-18 Genzyme Corporation Methods for the quantitation of polypeptides
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
KR20210075129A (ko) * 2018-10-09 2021-06-22 사노피 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법
US12459989B2 (en) * 2018-11-21 2025-11-04 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (HIV)
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
WO2020210392A1 (en) * 2019-04-09 2020-10-15 Sanofi Trispecific binding proteins, methods, and uses thereof
BR112022007664A2 (pt) 2019-10-25 2022-08-09 Sanofi Sa Métodos para analisar o pareamento incorreto de cadeias em proteínas de ligação multiespecíficas
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
CA3187085A1 (en) 2020-08-25 2022-03-03 Manuel Baca Multi-specific antigen binding molecules targeting hiv and methods of use
CA3232365A1 (en) * 2021-09-29 2023-04-06 Ronnie Rong Wei Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv
MX2024003808A (es) * 2021-09-29 2024-06-11 Modex Therapeutics Inc Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos.
CN118591388A (zh) * 2021-09-29 2024-09-03 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2025108551A1 (en) 2023-11-23 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025109206A1 (en) 2023-11-22 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
US20250376537A1 (en) 2024-05-17 2025-12-11 Sanofi Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
NZ527591A (en) 2001-01-17 2006-04-28 Trubion Pharmaceuticals Inc Binding domain-immunoglobulin fusion proteins
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
US8637024B2 (en) 2010-11-12 2014-01-28 The Rockefeller University Fusion antibodies for HIV therapy
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP3865507A1 (en) * 2011-05-17 2021-08-18 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
WO2013070776A1 (en) 2011-11-07 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing gp41 antibodies and their use
ES2749349T3 (es) * 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
CN108676091B (zh) 2011-12-08 2022-04-01 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
WO2014089152A1 (en) 2012-12-04 2014-06-12 University Of Maryland, Baltimore Hiv-1 env-binding antibodies, fusion proteins, and methods of use
HK1213481A1 (zh) 2012-12-13 2016-07-08 The Trustees Of The University Of Pennsylvania Dna抗体构建体及其使用方法
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
EA201891502A1 (ru) 2013-02-26 2018-12-28 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2014144299A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
BR112016009919A2 (pt) 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US10961506B2 (en) 2014-09-04 2021-03-30 Stemcell Technologies Inc. Soluble antibody complexes for T cell or NK cell activation and expansion
EP3247725B1 (en) 2015-01-23 2020-07-01 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
EP3298389B1 (en) 2015-05-20 2021-09-29 Quantum-Si Incorporated Method of determining the sequence of a nucleic acid using time resolved luminescence
US10654943B2 (en) 2015-06-02 2020-05-19 The Rockefeller University Tri-specific antibodies for HIV therapy
MX2018003463A (es) 2015-09-22 2018-09-06 Univ Pennsylvania Método de redireccionamiento de células t para tratar la infección por virus de inmunodeficiencia humana (vih).
PE20181167A1 (es) 2015-10-25 2018-07-19 Sanofi Sa Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
EA201891186A1 (ru) 2015-12-15 2018-12-28 Джилид Сайэнс, Инк. Антитела, нейтрализующие вирус иммунодефицита человека
HUE063824T2 (hu) 2016-04-13 2024-02-28 Sanofi Sa Trispecifikus és/vagy trivalens kötõfehérjék
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
US12234479B2 (en) 2016-12-30 2025-02-25 Cytocares (Shanghai) Inc. Bifunctional molecule and use thereof
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US11845787B2 (en) 2017-03-27 2023-12-19 The Wistar Institute Of Anatomy And Biology DNA antibody constructs for use against HIV
JP7036909B2 (ja) 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
KR20210075129A (ko) 2018-10-09 2021-06-22 사노피 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021072847A (ja) * 2015-10-25 2021-05-13 サノフイＳａｎｏｆｉ Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質
JP2023085476A (ja) * 2015-10-25 2023-06-20 サノフイ Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質
JP7724814B2 (ja) 2015-10-25 2025-08-18 サノフイ Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質

Also Published As

Publication number Publication date
RS62437B1 (sr) 2021-11-30
HUE056608T2 (hu) 2022-02-28
BR112018008011A2 (en) 2018-10-30
HRP20211528T1 (hr) 2021-12-24
DOP2018000102A (es) 2018-11-30
AR106466A1 (es) 2018-01-17
CN117069855A (zh) 2023-11-17
KR102687212B1 (ko) 2024-07-19
EP3819310A1 (en) 2021-05-12
US20200054765A1 (en) 2020-02-20
CN109311966A (zh) 2019-02-05
AU2024200395A1 (en) 2024-04-11
EP3365366B1 (en) 2021-07-14
EP3365366A1 (en) 2018-08-29
TW202442675A (zh) 2024-11-01
PE20181167A1 (es) 2018-07-19
IL301140A (en) 2023-05-01
AU2016347058B2 (en) 2023-11-09
US11129905B2 (en) 2021-09-28
CO2018005337A2 (es) 2018-07-10
IL258822B2 (en) 2023-08-01
CN116789841A (zh) 2023-09-22
CL2018001065A1 (es) 2018-11-23
US20220226495A1 (en) 2022-07-21
EA201891028A1 (ru) 2019-02-28
CN109311966B (zh) 2023-03-10
ES2894304T3 (es) 2022-02-14
IL258822A (en) 2018-06-28
TW201730210A (zh) 2017-09-01
TWI750139B (zh) 2021-12-21
PH12018500873A1 (en) 2018-11-12
HK1253385A1 (zh) 2019-06-14
US20190054182A1 (en) 2019-02-21
NZ742825A (en) 2024-04-26
CA3002664A1 (en) 2017-05-04
JP7328267B2 (ja) 2023-08-16
US20250312475A1 (en) 2025-10-09
UY36965A (es) 2017-05-31
US11779651B2 (en) 2023-10-10
SI3365366T1 (sl) 2022-02-28
JP2018537966A (ja) 2018-12-27
CR20180288A (es) 2018-09-11
CN116675776A (zh) 2023-09-01
IL258822B1 (en) 2023-04-01
WO2017074878A8 (en) 2018-05-24
SG11201803324VA (en) 2018-05-30
KR20180063336A (ko) 2018-06-11
MX2018005048A (es) 2018-09-06
MX2022014631A (es) 2023-01-11
PL3365366T3 (pl) 2022-01-31
NZ781602A (en) 2025-07-25
JP2023085476A (ja) 2023-06-20
MY192278A (en) 2022-08-16
WO2017074878A1 (en) 2017-05-04
TW202219064A (zh) 2022-05-16
AU2016347058A1 (en) 2018-06-14
JP2021072847A (ja) 2021-05-13
JP7724814B2 (ja) 2025-08-18
MA42641A1 (fr) 2019-03-29

Similar Documents

Publication Publication Date Title
JP7328267B2 (ja) Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質
TWI856979B (zh) 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法
JP7664175B2 (ja) 三重特異性結合性タンパク質、方法、およびその使用
JP7676316B2 (ja) Ｈｉｖ感染症の処置のためのクロスオーバー二重可変ドメイン（ｃｏｄｖ）フォーマットを使用した三重特異性および／または三価結合性タンパク質
CN116496389A (zh) 用于治疗hbv感染及相关疾病的表位肽及抗体
HK40052791A (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
HK1253385B (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EA040589B1 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221028

R150 Certificate of patent or registration of utility model

Ref document number: 7169190

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250